Iontophoresis of vidarabine monophosphate for herpes orolabialis

Louis P. Gangarosa, James M. Hill, Barry L. Thompson, Carol Leggett, John Peter Rissing

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

The cutaneous application of antiviral agents was studied by iontophoresis, a process that increases penetration of most drugs 20- to 60-fold. Twenty-seven subjects with vesicular orolabial herpes were treated one time in a double-blind, placebo-controlled clinical study: nine received vidarabine monophosphate (ara-AMP), nine received acyclovir (ACV), and nine received NaCl. Ara-AMP-treated lesions yielded lower titers of virus after 24 hr compared with lesions treated with NaCl or ACV (P < .05) and time to dry crust (P < .05) compared with the other two agents. There was a trend toward decreased healing time after ara-AMP treatment.

Original languageEnglish (US)
Pages (from-to)930-934
Number of pages5
JournalJournal of Infectious Diseases
Volume154
Issue number6
DOIs
StatePublished - Jan 1 1986

Fingerprint

Vidarabine Phosphate
Iontophoresis
Acyclovir
Viral Load
Antiviral Agents
Placebos
Skin
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Cite this

Iontophoresis of vidarabine monophosphate for herpes orolabialis. / Gangarosa, Louis P.; Hill, James M.; Thompson, Barry L.; Leggett, Carol; Rissing, John Peter.

In: Journal of Infectious Diseases, Vol. 154, No. 6, 01.01.1986, p. 930-934.

Research output: Contribution to journalArticle

Gangarosa, Louis P. ; Hill, James M. ; Thompson, Barry L. ; Leggett, Carol ; Rissing, John Peter. / Iontophoresis of vidarabine monophosphate for herpes orolabialis. In: Journal of Infectious Diseases. 1986 ; Vol. 154, No. 6. pp. 930-934.
@article{5c72f3c328324c5bbd891d035fe7c96c,
title = "Iontophoresis of vidarabine monophosphate for herpes orolabialis",
abstract = "The cutaneous application of antiviral agents was studied by iontophoresis, a process that increases penetration of most drugs 20- to 60-fold. Twenty-seven subjects with vesicular orolabial herpes were treated one time in a double-blind, placebo-controlled clinical study: nine received vidarabine monophosphate (ara-AMP), nine received acyclovir (ACV), and nine received NaCl. Ara-AMP-treated lesions yielded lower titers of virus after 24 hr compared with lesions treated with NaCl or ACV (P < .05) and time to dry crust (P < .05) compared with the other two agents. There was a trend toward decreased healing time after ara-AMP treatment.",
author = "Gangarosa, {Louis P.} and Hill, {James M.} and Thompson, {Barry L.} and Carol Leggett and Rissing, {John Peter}",
year = "1986",
month = "1",
day = "1",
doi = "10.1093/infdis/154.6.930",
language = "English (US)",
volume = "154",
pages = "930--934",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Iontophoresis of vidarabine monophosphate for herpes orolabialis

AU - Gangarosa, Louis P.

AU - Hill, James M.

AU - Thompson, Barry L.

AU - Leggett, Carol

AU - Rissing, John Peter

PY - 1986/1/1

Y1 - 1986/1/1

N2 - The cutaneous application of antiviral agents was studied by iontophoresis, a process that increases penetration of most drugs 20- to 60-fold. Twenty-seven subjects with vesicular orolabial herpes were treated one time in a double-blind, placebo-controlled clinical study: nine received vidarabine monophosphate (ara-AMP), nine received acyclovir (ACV), and nine received NaCl. Ara-AMP-treated lesions yielded lower titers of virus after 24 hr compared with lesions treated with NaCl or ACV (P < .05) and time to dry crust (P < .05) compared with the other two agents. There was a trend toward decreased healing time after ara-AMP treatment.

AB - The cutaneous application of antiviral agents was studied by iontophoresis, a process that increases penetration of most drugs 20- to 60-fold. Twenty-seven subjects with vesicular orolabial herpes were treated one time in a double-blind, placebo-controlled clinical study: nine received vidarabine monophosphate (ara-AMP), nine received acyclovir (ACV), and nine received NaCl. Ara-AMP-treated lesions yielded lower titers of virus after 24 hr compared with lesions treated with NaCl or ACV (P < .05) and time to dry crust (P < .05) compared with the other two agents. There was a trend toward decreased healing time after ara-AMP treatment.

UR - http://www.scopus.com/inward/record.url?scp=0023020053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023020053&partnerID=8YFLogxK

U2 - 10.1093/infdis/154.6.930

DO - 10.1093/infdis/154.6.930

M3 - Article

VL - 154

SP - 930

EP - 934

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 6

ER -